This expert-led discussion will unpack the unique translational challenges and opportunities for T-cell engagers across oncology and autoimmune indications. Panelists will explore how emerging scientific insights, target biology, and mechanistic understanding can inform smarter therapeutic design, combination strategies, and clinical development pathways for both cytotoxic and tolerability-driven indications.

• How does target biology influence format selection, CD3 affinity tuning, and tissue-selective delivery approaches in solid tumours vs autoimmune tissues?
• What translational tools (e.g., biomarkers, PD readouts, in vitro/in vivo models) are proving most predictive for efficacy and safety in both therapeutic areas?
• What combination strategies are most promising e.g., with checkpoint inhibitors, cytokines, or tolerance inducing agents and how do we time them?
• Where are current translational models falling short, and how can we better model immune engagement, off-tumour effects, and chronic exposure?
• How do we de-risk multi-targeting and immune activation in non-lethal diseases where tolerance, durability, and safety thresholds differ from oncology?